Skip to main
ELAN

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health is a global animal health company with a diverse portfolio and strong presence in the market, which is one of the fundamental reasons for the positive outlook. Acquisitions of Janssen Animal Health, Novartis Animal Health, Boehringer Ingelheim Vetmedica, and Bayer Animal Health have expanded the company's product offerings and global reach. Management's focus on accelerating price taking and avoiding innovation air pockets, combined with an increase in revenue, adj. EBITDA, and adj. EPS guidance, also contribute to the positive outlook.

Bears say

Elanco Animal Health is an established player in the animal health market with a newly launched product cycle that has yielded 7 potential blockbuster launches, which are expected to drive sales growth, margin improvement and deleveraging. However the company faces potential risks from competition and macroeconomic factors, and its product demand can be affected by weather conditions. Its guidance issued at the December 2025 Investor Day provides some visibility on the management's outlook, and the progress in its pipeline could provide potential upside.

ELAN has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 10 analysts, ELAN has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.